Mobile

A double-blind dose-response phase II, multicentre study of radium-223 (Alpharadrin ™) for the palliation of painful bone metastases in hormone refractory prostate cancer patients

Mise à jour : Il y a 4 ans
Référence : EUCTR2004-000299-15

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to investigate whether there is a dose-response relationship for radium-223 in patients with painful bone metastases secondary to prostate carcinoma regarding the palliation of bone pain.

Critère d'inclusion

  • Patients with painful bone metastases secondary to prostate carcinoma

Liens